Introduction
============

Opportunistic invasive fungal infections are a major cause of morbidity and mortality in immunocompromised patients. The clinical spectrum of patients who are at risk for invasive pulmonary aspergillosis (IPA) is broad. Patients receiving allogeneic bone marrow transplant, and who have neutropenia and haematological malignancy have a high risk for IPA. Further, patients receiving autologous bone marrow transplant, those with malnutrition, those receiving corticosteroids, HIV patients, those receiving solid organ transplant, diabetes patients, patients with underlying pulmonary diseases, and those with solid organ cancer have an intermediate risk for IPA, whereas patients with cystic fibrosis or connective tissue disease have a low risk for IPA[@B1]-[@B3]. IPA is a devastating infectious disease in intensive care unit (ICU) patients, as well as in those without any apparent predisposing immunodeficiency[@B4]-[@B6]. Patients with severe liver disease are at a heightened risk for infections. Acute-on-chronic liver failure (ACLF) is a life-threatening clinical syndrome with a complicated etiology, varied manifestations and a short-term mortality rate. Liver transplant seems to be an effective option to prolong survival in these group of patients, although it still can be followed by serious complications. Some studies have focused on IPA happening after liver transplantation[@B3],[@B7]. It was reported invasive fungal infections (IFI) was related to high rates of morbidity and mortality in these group of patients and invasive aspergillosis tended to occur earlier in the post-transplant period[@B3]. But few studies have focused on Aspergillus infections in such groups of patients during pre-transplant period. They either researched the patients with HBV-related liver failure or those with hepatic failure without definite type[@B8],[@B9]. The risk factors for and the clinical characteristics of IPA among patients with acute chronic liver failure (ACLF) remains unclear.

Objectives
==========

In this retrospective-cohort study conducted over a 41-month period, was aimed at analysing the clinical characteristics of and the risk factors for the development of IPA in ACLF patients at our institution. We also focused on the survival rate of ACLF patients with IPA and the effects of different kinds of antifungal treatments on survival.

Patients and Methods
====================

Patients
--------

The liver disease databases of the hospital were reviewed, and consecutive patients diagnosed with ACLF, with and without IPA, were included in this retrospective study. Eligible patients had attended the First Affiliated Hospital, School of Medicine, Zhejiang University from 1 December 2008 to 1 May 2012. The follow-up continued until the date of death, date of last hospital visit, or the end of the study (30 July 2012). The minimum follow-up period for enrolled patients was 3 months after discharge. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by The Human Ethics Committee of the First Affiliated Hospital, School of Medicine, Zhejiang University. Informed consent was obtained from each patient included in the study. All patients received treatment in the intensive care unit (ICU) for the prevention and treatment of complications of ACLF as well as etiological treatment based on the cause of ACLF. Other conventional treatments including energy supplements were provided for the maintenance of electrolyte and acid base equilibriums.

Enrolment criteria
------------------

ACLF was defined according to following criteria specified by the Asian Pacific Association for the Study of the Liver (2009)[@B10]and Guideline for Diagnosis and Treatment of Liver Failure in China (2006)[@B11]: (1) the acute deterioration of pre-existing chronic liver disease; (2) extreme fatigue with severe digestive symptoms such as obvious anorexia, abdominal distension, or nausea and vomiting; (3) progressively worsening jaundice within a short period (serum total bilirubin ≥10 mg/dL or a daily elevation of ≥1 mg/dL); and (4) an obvious haemorrhagic tendency with prothrombin activity (PTA) ≤40%. The absence of any of the above 4 criteria precluded a diagnosis of ACLF.

We used the EORTC/MSG consensus definition of probable invasive *Aspergillus* infection, which was diagnosed if the following 2 criteria were fulfilled: 1 microbiologic criterion (positive sputum culture); and 1 major clinical criterion or 2 of minor clinical criteria (computed tomography signs suggesting lower respiratory tract infection. Proven IPA was diagnosed if fungal infection in the tissue was established by biopsy or a needle aspirate. In our study, a diagnosis of probable IPA was made on the basis of the following: (1) sputum culture positive for *Aspergillus* spp*.*; (2) bilateral nodular infiltrates with central cavitation, bilateral alveolar infiltrates, or homogeneous infiltrates in the right upper lobe; (3) the halo or air-crescent sign (a macronodule surrounded by a perimeter of ground-glass opacity) on the CT image; and (4) at least 2 minor clinical findings (signs of lower respiratory tract infection, pleural rub, and presence of any new infiltrate in a patient who did not fulfil the major criteria, but for whom an alternative diagnosis was unavailable). In brief, a diagnosis of probable IPA was made on the basis of the appearance of pulmonary consolidation or infiltrate on the thoracic image and rapid progression with antibiotic-resistant fever in the host as well as a sputum culture positive for *Aspergillus* spp.

ACLF patients whose chest radiograph or CT scans did not show infiltrates in the lung were included as controls.

Risk factors for IPA and mortality
----------------------------------

The following 9 variables were assessed as risk factors for IPA: sex, age, smoking history, diabetes mellitus type 2, chronic bronchitis, steroid use, antibiotics type, encephalopathy, and neutropenia. The survival time for patients with ACLF was defined as the period from diagnosis of liver failure to death or the end of the study (30 July 2012). Patients who remained alive until the end of the study were censored. Survival time for ACLF patients with IPA was defined as the period from the diagnosis of IPA to death or the end of the study. Overall mortality included all deaths that occurred before the last investigation. IPA attributable mortality means the death was not clearly attributed to another cause except IPA.

Statistical analysis
--------------------

Continuous variables were compared using the Mann-Whitney test, and categorical data were compared using the chi-squared test. P-values \< 0.05 were considered statistically significant for all analyses. Logistic regression was performed to identify risk factors associated with IPA in ACLF patients. A significant relationship with IPA was used as the criterion for including a variable in the multivariate stepwise modelling procedure. In the stepwise procedure, to determine the independent risk factors, we used a 0.05 significance level for entering and a 0.10 significance level for removing explanatory variables. Mortality rates among ACLF patients, with and without IPA, were plotted using the Kaplan-Meier method and compared by log-rank analysis. Survival among ACLF patients with IPA stratified by the drugs used for treatment was compared using Kruskal-Wallis analysis. A software program (SPSS16.0) was used for the statistical analyses.

Results
=======

We identified 787 patients who were diagnosed with ACLF from 1 December 2008 to 1 May 2012. Thirty-nine patients had IPA; 48 patients without any pulmonary infection were included in the control group. The demographic and clinical characteristics of the study patients are presented in Table [1](#T1){ref-type="table"}.

The subjects included 70 men and 17 women, with a median age of 39 years (range, 24-69 years). The underlying liver disease in these patients was caused by viral infection, autoimmune hepatitis, primary biliary cirrhosis, schistosomiasis, alcoholic addiction, and/or unknown reasons. Sixty patients received antibiotics for fever or the prevention of treatment complications, and 47 patients received steroids to reduce inflammation. Only 3 patients had neutropenia.

All 39 patients with IPA had a cough with expectoration, whereas 16 of these patients had hemoptysis. All 39 patients had a fever, and 12 had an initial fever lower than 38.5°C. Among the patients with IPA, 36 presented with at least 1 macronodule with central cavitation on the chest CT scan, and 30 of these patients had multiple macronodules. Thirty-seven patients presented with infiltrates in 1 or both lungs. Twenty-eight patients had at least 1 halo or air-crescent sign.

Intravenous antifungal drugs such as caspofungin, itraconazole, or voriconazole were administered to patients diagnosed with IPA. However, some patients were not treated with antifungal therapy because they were discharged from hospital or died before the culture results were available. Twenty-four patients died due to respiratory failure in spite of treatment with antifungal drugs.

Risk factors for IPA and all-causes mortality
---------------------------------------------

In our retrospective analysis, multivariate logistic-regression analysis showed that age (*p*= 0.021), hepatic encephalopathy (*p*= 0.001), and steroid use (*p*= 0.000) were independent risk factors associated with IPA (Table [2](#T2){ref-type="table"}). Furthermore, in patients who died after fungal infection, the mean time from the diagnosis of IPA to death was 4.2 (1-26) days. The all-causes mortality rate of ACLF patients with IPA was 94.87% (37 of 39 patients). IPA attributable mortality was 61.54% (24/39). HE caused mortality was 28.2% (11/39). HRS attributable mortality was 5.13% (2/39).

All 48 ACLF patients without IPA were alive until the end of follow-up (30 July 2012). The survival rate of IPA patients was significantly lower than that of those without IPA (Figure [1](#F1){ref-type="fig"}).

Influence of drug use on the survival time and IPA attributable death rate of ACLF patients with IPA
----------------------------------------------------------------------------------------------------

Eight of the 10 patients taking caspofungin died within 7 days with median time of antifungal therapy of 2 days (range from 1 to 890 days). Five of the 9 patients taking voriconazole died within 7 days with median time of 6 days (range from 1 to 148 days). Four of the 7 patients taking itraconazole died within 7 days with median time of 2 days (range from 2 to 6 days). The rest 13 patients did not receive any antifungal drugs and the median survival time was 2 days (range from 1 to 6 days). Totally twenty four of 39 patients were dead with progression of fungal infection. Thirteen of 39 patients had partial response but were dead with progression of liver failure. The rest patients (2/39) got complete response and recovered after being administered either voriconazole or caspofungin. The patient was treated with voriconazole for 73 days till the infectious lesion in lung was completely absorbed on the CT image and had been alived for 148 days from diagnosis to the end of study. The patient with caspofungin had been alived for 890 days with the duration of the initial antifungal therapy for 42 days. Kruskal-Wallis analysis showed there was a significant difference in the survival time of patients within three different drugs (*p* = 0.011). Further analysis showed there was a significant difference between the survival time of patients who were administered itraconazole (*p* = 0.003) or voriconazole (*p* = 0.015) and those who were not administered antifungals without consideration of the duration of antifungal therapy.

Because of the severity of ACLF, 15 patients received drugs for less than 5 days before death and were dead due to infections or other complications (Table [3](#T3){ref-type="table"}). Only 11 patients got the antifungal therapy for longer than 5 days, but 45.4% patients (5/11) still were dead because of respiratory failure due to IPA. If patients who had received less than 5 days of drug were considered as those "not treated", the IPA attributable death rate was 67.8% (19/28). But there was no difference in IPA attributable death rate between these two groups (*p*= 0.691). There were also no differences in the constituent ratio of death among patients with different drugs and those not treated (*p* = 0.339).

Discussion
==========

Fungal infections are observed in patients with various diseases, especially among immunodeficient patients such as those who receive stem cell transplantation. Although IPA has been reported in patients after liver transplantation[@B3],[@B7],[@B12], IPA has rarely been observed in patients with other liver diseases. Early diagnosis of IPA is difficult; therefore, research has focused on the identification of patients at a high risk for IPA so that antifungal prophylaxis and empirical treatment improves their survival. The patients in our study did not belong to any of the high-risk groups (patients with neutropenia, those receiving bone marrow transplant, or patients with hematological malignancy). Initially, patients with cancer, irrespective of whether or not they received hematopoietic stem cell transplantation, were considered to have a high risk for IPA, as per the Consensus guidelines (2004)[@B13]. In 2009, consensus guidelines revised the definition to include immunocompromised patients[@B14], but not critically ill patients such as ACLF patients. In our study, IPA incidence was about 5%, which is as high as some hematological malignancies. There may be some similarities between these two different diseases. The first lines of host defense to aspergillus is respiratory epithelium which may be damaged due to chemotherapy or infection[@B15]. Then the secretion of cytokines, chemokines by the macrophages plays an important role in the coordination of innate and adaptive cellular responses to aspergillus infection[@B16] The successive lines of cellular defense are polymorphonuclear neutrophils and monocytes[@B17],[@B18]. Prolonged neutropenia after chemotherapy has been reported to be associated with a poor prognosis in patients with hematological malignancies[@B19]. Researches showed there was a possibility of qualitative defects (impaired phagocytosis and killing of pathogens) of circulating neutrophils and granulocyte colony-stimulating factor can improve function of neutrophils from patients with acute liver failure[@B20],[@B21]. The last host defense for developing invasive aspergillus infection is T-lymphocyte helper (Th) cells which exhibit successful selection and clonal expansion of direct professional effector cells with activity against *Aspergillus*[@B22],[@B23]. Dysregulation of the host adaptive Th1/Th2 polarization may play a key role in the subacute progression of invasive aspergillosis not only in hematological malignancies but liver failure[@B24],[@B25].

Reduced cellular immune function might contribute to the increased infectious morbidity of these patients with ACLF. Patients diagnosed with probable IPA may, in fact, have a proven infection. If the tissue is positive for fungal infections, the host factors can be omitted. However, the diagnosis of proven IPA is difficult because of coagulation disorder of the patients with ACLF. Therefore, it is unfeasible to obtain the infectious tissue through invasive procedures. In our study, only 1 patient had evidence of fungal infection in the tissue (data not shown).

Hence, we analysed the relationship of 9 variables with the development of IPA. The previous study showed multiple antibiotics use and frequent invasive procedures were independent factors associated with the occurrence of IPA in patients with HBV-related liver failure[@B8]. And the patients were prone to many types of infections caused by opportunistic pathogens including *Aspergillus spp.* when using multiple antibiotics. However in our study results showed there was no significant difference in antibiotics use between the patients with IPA and those without lung infection. Instead, age, encephalopathy, and steroid use were significant risk factors for IPA. All 3 factors indirectly reflect the immune status. Encephalopathy is known to be closely related to the high mortality of liver failure. Moreover, as we know *Aspergillus* can be detected throughout the environment. For patients in a coma, encephalopathy increases the chance of aspiration which may induce infection. Although not all the patients used steroids, mortality was much higher in those who were given steroids. Corticosteroids influence phagocyte function by the impairment of phagocytosis, oxidative burst, cytokine and chemokine production, and cellular migration[@B26]. Several studies have demonstrated that corticosteroids impair the functional ability of phagocytes to kill *A. fumigatus* conidia and hyphae[@B27]-[@B29], and it has been listed as a host factor in the diagnosis of IPA.

*Aspergillus fumigatus,* which was found to be sensitive to azole, was the most common species identified in our study (data not shown in result). It is the primary causative agent of fungal infections in humans, followed by *A. flavus*, *A. terreus*, and *A. Niger[@B2],[@B30].* In our study, more than half of ACLF patients with IPA died due to respiratory failure despite antifungal therapy. Although voriconazole and itraconazole may prolong the life time of ACLF patients with IPA, there were no differences in IPA attributable death rate and another reasons attributable death rate among the patients with or without drugs. Moreover most of patients had not enough time to be treated with antifungal drugs and dead with IPA induced respiratory failure. So we took this into consideration and found there was also no difference in the constituent ratio of death among patients with different drugs and those not treated including those without enough duration. IPA attributable death rate with drugs was lower than those not treated. It was suggested antifungal therapy may reduce IPA attributable death, but there was no statistically difference. Maybe the numbers of patients enrolled in the study were too limited to make a real comparison. Much more cases should be further studied. Moreover, we know that voriconazole may induce liver and kidney injuries. The dose should be adjusted according to the underlying kidney or liver diseases. But in our study the doses for the surviving patient were not changed even though he had abnormally high total bilirubin levels. Despite the poor prognosis of aspergillosis, liver and renal function did not worsen after treatment, and the patient still recovered progressively and survived till the last investigation. Maybe he was young enough to be cured by an antifungal agent.

It has been reported that IPA attributable mortality rate ranges from 17.3% to 90% in high-risk populations and depends on the host factors, site of infection, and the treatment regimen applied[@B31],[@B32]. The mortality due to ACLF is still very high, although artificial liver support system and liver transplantation can reduce the mortality[@B33],[@B34]. Patients treated in more recent years may have better outcomes because of new developments in diagnosis and early treatment with new antifungal drugs, but the mortality rate of ACLF due to IPA was still as high as 61% in our study, suggesting that IPA may be an important predictor of mortality in ACLF patients. There are some possible reasons: 1. The severity of the cellular immunocompromise of ACLF which was discussed above made patients vulnerable to the infection of aspergillus. 2. In such kind of patients the coagulation disorder contributed to the hemorrhage of upper respiratory tract easily when aspergillus invased into the alveolar vessels. 3. In our study it was late to begin the antifungal therapy although immediately after the culture result was known. Moreover, almost one-third patients did not receive the antifungal drugs. Patients may miss the best time for the treatment. So early diagnosis of IPA and an earlier treatment may improve the prognosis of these patients. Physicians unfamiliar with the clinical manifestations of IPA may not consider symptoms such as a relatively low fever with cough or chest pain. In addition, they may believe that the sputum culture was positive because of contamination and miss the opportunity for treatment. Further, some patients in our study may not have obtained a CT scan. The new*Aspergillus* galactomannan EIA was approved by the FDA[@B35],[@B36]. However, our hospital did not conduct the GM-test regularly, which may have resulted in substantial underdiagnosis and delay in treatment. To determine whether prophylaxis was useful in improving the prognosis, additional studies are needed with more number of patients.

In summary, patients with ACLF were immunocompromised hosts who were prone to IPA, and the mortality rate of these patients is high. The greatest risk factor for infection is use of steroids, which increases the susceptibility of the patient to IPA. What\'s more, ACLF patients with encephalopathy should not be treated using steroids, as they increase the mortality rate further. When a GM test cannot be performed and symptoms of pneumonia such as cough or hemoptysis in ACLF appear, IPA should be considered. Hence, once patients with ACLF are diagnosed with IPA, antifungal therapy should be initiated immediately. However, data on prophylaxis chemotherapy are lacking, and then, additional investigation is necessary. Although the use of voriconazole without adjusting the dose did not negatively impact liver and renal function in the current study, we should closely monitor liver and renal function effects in patients with ACLF.
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###### 

Demographic and clinical characteristics of patients with acute-on-chronic liver failure enrolled in the study, who were diagnosed with invasive pulmonary aspergillosis (n=39) or without pulmonary infection (n=48).

  ----------------------------------------------------------------------------------------------------------------------------------
  Baseline characteristics         Patients\                         Patients\                                           *p* value
                                   without pulmonary infection(%)\   with invasive pulmonary aspergillosis(%) (n = 39)   
                                   (n = 48)                                                                              
  -------------------------------- --------------------------------- --------------------------------------------------- -----------
  Sex (male/female)                41/7                              29/10                                               0.196

  Age (mean ± sd) (years)          37.5 ± 9.16                       43 ± 11.65                                          0.003^\*^

  Smoking history                  13(27.1)                          15(38.5)                                            0.259

  Underlying liver disease                                                                                               

  hepatitis B virus infection      44(91.7)                          37(94.9)                                            0.560

  hepatitis E virus infection      1(2.1)                            0                                                   0.367

  primary biliary cirrhosis        0                                 1(2.6)                                              0.267

  autoimmune hepatitis             1(2.1)                            2(5.1)                                              0.442

  schistosomiasis                  0                                 1(2.6)                                              0.115

  acute fatty liver of pregnancy   1(2.1)                            0                                                   0.367

  alcohol addiction                3(6.3)                            3(7.7)                                              0.793

  unknown reason                   1(2.1)                            0                                                   0.367

  Other underlying disease                                                                                               

  cardiovascular disease           2(4.2)                            6(15.4)                                             0.073

  diabetes mellitus type 2         0                                 2(5.1)                                              0.115

  Chronic bronchitis               1(2.1)                            4(10.2)                                             0.173

  Complications                                                                                                          

  hepatic encephalopathy           4(8.3)                            24(61.5)                                            0.000^\*^

  upper gastric bleeding           1(2.1)                            1(2.6)                                              0.882

  hepatic renal syndrome           0                                 11(28.2)                                            0.000^\*^

  ascites                          30(62.5)                          32(82)                                              0.046

  Neutropenia                      2(4.2)                            1(2.6)                                              0.831

  Broad-spectrum\                  25(52.1)                          35(89.7)                                            0.006^\*^
  antibiotics usage                                                                                                      

  One antibiotic                   15(31.2)                          16(41)                                              0.347

  Two antibiotics                  6(15.4)                           12(30.8)                                            0.038

  More than 2 antibiotics          4(8.3)                            7(17.9)                                             0.182

  Steroid use                      12(25)                            35(89.7)                                            0.000^\*^
  ----------------------------------------------------------------------------------------------------------------------------------

*^\*^p*\<0.01

###### 

Logistic regression analysis of risk factors associated with invasive pulmonary aspergillosis among patients with acute-on-chronic liver failure.

                           B       *p*value   HR       95% C.I. for HR   
  ------------------------ ------- ---------- -------- ----------------- --------
  Age                      0.711   0.021      2.036    1.111             3.730
  Hepatic encephalopathy   2.348   0.001      10.464   2.471             44.321
  Steroid usage            2.914   0.000      18.437   4.352             78.107

B: partial regression coefficient; HR: hazard ratio; CI: confident interval.

###### 

The characteristics of ACLF patients with IPA treated with or without anti-fungal drugs.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                                Caspofungin\   Voriconazole (%) (n=9)   Itraconazole (%) (n=7)   Without antifungal therapy (%) (n=13)   *p* value
                                                 (%) (n=10)                                                                                               
  ---------------------------------------------- -------------- ------------------------ ------------------------ --------------------------------------- -----------
  Sex(male/female)                               9/1            6/3                      4/3                      10/3                                    0.468

  Age (mean ± sd) (years)                        39.9±11.1      51.0±12.2                43.8±9.7                 45.8±11.9                               0.221

  Survival time\                                 92±280         23±47                    6±5                      2±1                                     0.011
  (mean ± sd)(days)                                                                                                                                       

  **Duration of antifungal therapy ≥ 5 days**                                                                                                             

  **Reasons for death**                                                                                                                                   

  Respiratory failure                            1(10.0)        2(22.2)                  2(28.6)                                                          

  Hepaitc encephalopathy                         1(10.0)        2(22.2)                  0                                                                

  Hepatic renal syndrome                         0              0                        1(14.3)                                                          

  **Duration of antifungal therapy \< 5 days**                                                                                                            

  **Reasons for death**                                                                                                                                   

  Respiratory failure                            5(50.0)        4(44.8)                  2(28.6)                                                          

  Hepaitc encephalopathy                         1(10.0)        0                        2(28.6)                                                          

  Hepatic renal syndrome                         1(10.0)        0                        0                                                                
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
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